CounterX Therapeutics is developing antibody therapies to prevent opioid overdoses and support recovery. Its lead investigational candidate, CTRX-101, is a once-monthly injection designed to protect people at high risk of accidental fentanyl overdose. Behind the lead program is CounterXCL™, the company’s proprietary discovery platform for developing targeted antibody therapies and vaccines to address opioid overdose and dependence.
Fentanyl overdose is now the leading cause of death for Americans aged 18–45. CounterX Therapeutics has built CTRX-101, a once-monthly injectable antibody designed to prevent it.
Fentanyl overdose is now the leading cause of death for Americans aged 18–45. CounterX Therapeutics has built CTRX-101, a once-monthly injectable antibody designed to prevent it.
Fentanyl overdose is now the leading cause of death for Americans aged 18–45. CounterX Therapeutics has built CTRX-101, a once-monthly injectable antibody designed to prevent it.
Register Here to
View Pitch Deck
“This technology has the potential to fundamentally change how opioid overdoses are treated and addresses the ongoing public health crisis caused by illicit fentanyl.”
The Team
Shawn Iadonato, PhD
Founder & Chief Scientific Officer
A biotechnology entrepreneur with experience founding, financing and taking companies public. As CEO of Kineta, Shawn raised approximately $100 million in private and public equity financing and secured partnerships with Pfizer and Genentech/Roche, bringing drug-development, fundraising and strategic partnership experience to CounterX.
Marco Pravetoni, PhD
Founder & Chief Scientific Officer
A University of Washington professor and Director of its Center for Medication Development for Substance Use Disorders and Overdose. Marco’s research focuses on vaccines and antibody therapies to reduce fatal overdoses. He has published more than 80 peer-reviewed papers and received numerous NIH research awards.
Craig Philips
Chief Financial Office
A pharmaceutical executive with more than 35 years of experience across clinical development, commercialization and fundraising. Previously President of Kineta and CTI BioPharma, Craig’s experience includes launching four pharmaceutical products that each exceeded $1 billion in sales.
Jacques Bouchy
Chief Business Officer
A biopharmaceutical executive with more than 30 years of experience across business development, investor relations and commercialization. Jacques helped execute Kineta’s partnerships with Pfizer and Genentech and has launched twelve pharmaceutical products, bringing experience in pricing, payer access and commercial strategy.
Register Here to
View Pitch Deck
Register Here to
View Pitch Deck
Interested in Investing in Healthcare Innovation?
